Search | Influenza A(H1N1)

  • BIREME | OPAS | OMS logo
 
Results  1-12 de 241
1.

Guidance for businesses and employers to plan and respond to the 2009 - 2010 influenza season

Author(s): U.S. Department of Health & Human Services. Centers for Disease Control and Prevention
Source: s.l; Centers for Disease Control and Prevention; Aug. 19, 2009.
Repository Complementary ID: 258
Abstract: CDC is releasing new guidance that recommends actions that non-healthcare employers should take now to decrease the spread of seasonal flu and 2009 H1N1 flu in the workplace and to help maintain business continuity during the 2009û2010 flu season.1 The guidance includes additional strategies to use if flu conditions become more severe and some new recommendations regarding when a worker who is ill with influenza may return to work. The guidance in this document may change as additional inf (more)
2.

WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses

Author(s): World Health Organization - WHO
Source: s.l; World Health Organization; Aug. 20, 2009. 91 p. tab.
Repository Complementary ID: 262
Abstract: The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection as well the potential use of the medicines for chemoprophylaxis. The document addresses specifically the two neuraminidase inhibitors oseltamivir and zanamivir, and the two M2 inhibitors amantadine and rimantadine. It includes recommendations on the use of some other potential pharmacological treatm (more)
3.

Availability of a new candidate reassortant vaccine virus for pandemic (H1N1) 2009 virus vaccine development: NIBRG-121xp

Author(s): World Health Organization - WHO
Source: s.l; World Health Organization; Aug. 6, 2009. 2 p.
Repository Complementary ID: 264
Abstract: A new candidate reassortant vaccine virus (NIBRG-121xp) has been developed by extended egg passage of the reverse genetics technology derived reassortant NIBRG-121 originally developed from an A/California/7/2009(H1N1)v virus by the National Institute for Biological Standards and Control (NIBSC), Potters Bar, Hertfordshire, United Kingdom.
4.

Use of specific pandemic influenza vaccines during the H1N1 2009 pandemic

Author(s): European Centre for Disease Prevention and Control
Source: Stockholm; ECDC; Aug. 2009. 30 p.
Repository Complementary ID: 295
Abstract: This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services. The guidance is based on the experience of the current H1N1 pandemic to date. As the situation evolves, the guidance may be updated to reflect new developments.
5.

Guidance for Businesses and Employers To Plan and Respond to the 2009 - 2010 Influenza Season

Author(s): U.S.A. Centers for Disease Control and Prevention
Source: s.l; CDC; Aug. 19, 2009. 13 p.
Repository Complementary ID: 305
Abstract: The U.S. Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC), with input from the U.S. Department of Homeland Security (DHS), has developed updated guidance for employers of all sizes to use as they develop or review and update plans to respond to 2009 H1N1 influenza now and during the upcoming fall and winter influenza season. Businesses and employers, in general, play a key role in protecting employees\' health and safety, as well as in limiting (more)
6.

Availability of four new candidate reassortant vaccine viruses for pandemic (H1N1) 2009 virus vaccine development: IDCDC-RG18, IDCDC-RG20, IDCDC-RG22 and NIBRG-122

Author(s): World Wealth Organization
Source: s.l; WHO; July 22, 2009. 2 p.
Repository Complementary ID: 192
Abstract: Four new candidate reassortant vaccine viruses for pandemic (H1N1) 2009 vaccine development are available for distribution.
8.

Biocontainment requirements for vaccine production from and quality control of the reassortant candidate vaccine virus IVR-153

Author(s): World Health Organization
Source: s.l; WHO; July 6, 2009. 1 p.
Repository Complementary ID: 194
Abstract: Safety testing of the candidate reassortant vaccine virus IVR-153 has been completed according to WHO protocol
9.

Hand washing and personal protective equipment: information for health care managers

Author(s): Pan American Health Organisation
Source: Washington; PAHO; July 21, 2009. 10 p.
Repository Complementary ID: 208
Abstract: This document provides technical information on hand washing and the use of personal protective equipment(PPE) during the Influenza (H1N1) Pandemic, to mitigate the risk of transmission and accumulation of infected cases at national and community levels. It is intended for health care managers1 in all countries in the Regionof the Americas, which may or may not have probable or confirmed cases of infection. It will be revised as the situation evolves and additional information becomes available.(AU)
10.

The primary health care strategy and the response to the influenza (H1N1) pandemic

Author(s): Pan American Health Organisation
Source: Washington; PAHO; July 21, 2009. 5 p.
Repository Complementary ID: 209
Abstract: This document provides technical information and recommendations on organizing first level of care services and communities in response to the Influenza (H1N1) pandemic. It is intended for health care managers1 in all countries in the Region of the Americas, which may or may not have probable or confirmed cases of infection.It will be revised as the situation evolves and additional information becomes available.(AU)
11.

Responding to a second emergency during an influenza pandemic: recommendations for health care managers

Author(s): Pan American Health Organisation
Source: Washington; PAHO; July 21, 2009. 4 p.
Repository Complementary ID: 210
Abstract: This document provides technical recommendations on responding to a second emergency during the Influenza (H1N1) pandemic. It is intended for all countries in the Region of the Americas, in particular to those countries at risk of beingaffected by natural disasters (or any other type of emergency situation), while engaged in the response to the current H1N1 emergency. The recommendations will be revised as the situation evolves and additional information becomes available.(AU)
12.

Situação epidemiológica da nova influenza A (H1N1) no Brasil, 2009

Author(s): Brasil. Ministério da Saúde
Source: Boletim Eletrônico Epidemiológico;9(1): [9], Jul. 22, 2009. .
Repository Complementary ID: 211
Abstract: Desde a declaração de Emergência de Saúde Pública de Importância Internacional por influenzaA(H1N1), pela Organização Mundial da Saúde em 24 de abril de 2009, até a publicação da última notatécnica, o Brasil divulgou dados epidemiológicos de caso suspeitos, confirmados e descartadosindividualmente. Até aquele momento era possível estabelecer o vínculo com viagem ao exterior ou algumtipo de contato próximo. Em 16 de julho de 2009, após a conclusão da investigação epide (more)
Results  1-12 de 241